PURPOSE:
Patients undergoing autologous breast reconstruction are at high risk of perioperative venous thromboembolic events (VTE). The efficacy of chemoprophylaxis in decreasing VTE is well established but the timing of chemoprophylaxis remains controversial. Many surgeons are reluctant to initiate preoperative chemoprophylaxis due to concerns of bleeding. We compare the incidence of bleeding following preoperative versus postoperative initiation of chemoprophylaxis in microvascular breast reconstruction.
METHODS:
Patients undergoing autologous breast reconstruction from August 2010-July 2016 were reviewed. Initiation of chemoprophylaxis changed from postoperative to preoperative in 2013, dividing subjects into two groups. Patient demographics, comorbidities, and complications were reviewed.
RESULTS:
A total of 196 patients (311 flaps) were included in the study (mean age 51.4, SD 4.9; mean BMI 26). A total of 105 patients (166 flaps) received preoperative enoxaparin 40mg while 91 patients (145 flaps) received postoperative chemoprophylaxis. A total of four patients required hematoma evacuation, overall incidence of 2.04%. Of these, no hematomas (0%) occurred in the preoperative chemoprophylaxis group (p=0.045). Six patients received blood transfusions; two in the preoperative group, and four in the postoperative group (1.9% vs 4.4%, p=0.419). There was a total of one flap failure and no documented VTE in all groups.
CONCLUSION:
This study demonstrates that preoperative chemoprophylaxis can safely be used in patients undergoing microvascular breast reconstruction. The higher rate of bleeding in the postoperative group may be related to the onset of action of enoxaparin of 4-6 hours, which allows for intraoperative hemostasis in the preoperative group while possibly potentiating postoperative oozing when administered postoperatively. PURPOSE: Modern body armor, rapid evacuation and advanced combat casualty care have improved survival after catastrophic extremity and maxillofacial trauma. Vascularized composite allotransplantation (VCA) is a superior restorative option compared to traditional reconstruction in these complex injuries. To mitigate obligate reperfusion injury in VCA, we evaluate the efficacy of a novel normothermic hyperbaric oxygen warm ex-vivo perfusion strategy using hyperoxygenated Kidney Perfusion Solution (KPS) in a porcine VCA model.
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HYBERBARIC NORMOTHERMIC PERFUSION MITIGATES REPERFUSION
METHODS:
Gracilis myocutaneous flap autotransplants were performed heterotopically in the cervical area of Yorkshire swine. Group 1 (controls, n=5) flaps were perfused with cold KPS at 4ºC for three hours prior to transplant. Group 2 (experimental, n=5) flaps were perfused with hyper-oxygenated KPS for seven hours at 37ºC in a hyperbaric chamber at 3 atm before transplantation. Flaps were monitored daily for clinical evidence of viability and biopsied per protocol with an end point of 21 days. Histologic analysis was blinded.
RESULTS:
Autotransplants remained viable at the 21 day end point. Histological evaluation revealed extensive diffuse evidence of necrosis in all controls (at 3 hours, cold static preservation) but flaps placed on hyperbaric ex-vivo perfusion support showed decreased histologic evidence of ischemic injury or necrosis ranging from rare to moderate.
CONCLUSION:
Hyperbaric normothermic perfusion dramatically extends the viability of composite tissues ex-vivo. Injuries secondary to ischemia and cold preservation are mitigated. This technology has the potential to extend the window of time between procurement and transplantation in the growing field of Reconstructive Transplantation as well as solid organ transplants.
